Recombinant Proteins iso9001 ISO13485
搜索
 > 【FOLR1】重组蛋白信息

FOLR1信息

英文名称:Folate receptor alpha
中文名称:叶酸受体α
靶点别称:FRalpha,KB cells FBP,Adult folate-binding protein,Folate receptor 1,Folate receptor alpha,FR-alpha,FOLR1,Ovarian Tumor-Associated Antigen MOv18,Folate Receptor 1 (Adult),Folate Receptor, Adult,FOLR,FBP,Folate Binding Protein,FRα
上市药物数量:0
临床药物数量:10
最高研发阶段:临床三期

FOLR1 Molecule Synonym Name

FOLR-1,FBP,FOLR

FOLR1 分子背景

Folate Receptor 1 (FOLR1) is also known as Folate receptor alpha, Folate Binding Protein (FBP), FOLR, and is a member of the folate receptor (FOLR) family. Members of this gene family have a high affinity for folic acid and for several reduced folic acid derivatives, and mediate delivery of 5-methyltetrahydrofolate to the interior of cells. Mature FOLR1 is an N-glycosylated protein that is anchored to the cell surface by a GPI linkage. FOLR1 is predominantly expressed on epithelial cells and is dramatically upregulated on many carcinomas. FOLR1 is internalized to the endosomal system where it dissociates from its ligand before recycling to the cell surface. A soluble form of FOLR1 can be proteolytically shed from the cell surface into the serum and breast milk. Defects in FOLR1 are the cause of neurodegeneration due to cerebral folate transport deficiency (NCFTD). NCFTD is an autosomal recessive disorder resulting from brain-specific folate deficiency early in life.

FOLR1 参考文献

FOLR1临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
STRO-002 SP-7219; SP-7675; SP-7676; STRO-002; DBCO-Alexa647-conjugated SP7219 临床一期 Sutro Biopharma 卵巢癌, 卵巢上皮癌, 腹膜癌, 输卵管癌, 子宫内膜样癌, 子宫内膜癌 详情
MORAb-202 MORAb-202 临床二期 卫材株式会社, Morphotek 肿瘤 详情
MOv18 IgE (King's College London) 临床一期 伦敦国王学院, Cancer Research Uk 肿瘤 详情
OTL-38 EC-17; OTL-38; OTL-0038; Pteroyl-L-Tyr-S0456 临床三期 On Target 卵巢癌, 肾细胞癌, 肺癌 详情
EC-1456 EC-1456; EC-0531 临床一期 诺华制药 卵巢癌, 非小细胞肺癌 详情
GALE-302 E-39; J-65; GALE-302 临床二期 Galena Biopharma 卵巢癌, 乳腺癌
Farletuzumab MORAb-003 临床三期 Morphotek 卵巢癌, 肺腺癌, 卵巢上皮癌, 腹膜癌, 输卵管癌 详情
Noscapine-folate conjugate 临床一期 埃默里大学 血液肿瘤, 炎性疾病
Vintafolide EC-145; MK-8109 临床二期 诺华制药 卵巢癌, 肺腺癌, 肿瘤, 乳腺癌, 子宫内膜样癌, 非小细胞肺癌 详情
Mirvetuximab soravtansine IMGN-853; M9346-Asulfo-SPDB-DM4 临床三期 Immunogen Inc 卵巢癌, 卵巢上皮癌, 乳腺癌, 腹膜癌, 输卵管癌, 子宫内膜样癌 详情

消息提示

请输入您的联系方式,再点击提交!

确定